Trial Profile
A Phase 1, Double-blind, Randomized, Placebo-controlled, Ascending Multiple Oral Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MYK-461 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Mar 2017
Price :
$35
*
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions
- Sponsors MyoKardia
- 21 Mar 2017 Status changed from active, no longer recruiting to completed.
- 26 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2016 Results published in a MyoKardia media release.